You searched for "gene therapy"

173 results found

Using bupivacaine to the medical rectus in addition to lateral rectus recession for convergence insufficiency type intermittent exotropia

This is a retrospective study of 60 paediatric optic pathway glioma (OPG) patients (NF1 or sporadic) presenting to Great Ormond Street between 2003-2017. Median follow-up was 82 months. Analysis was divided into best and worst eye vision representing level quality...

Visual outcomes and predictors in optic pathway glioma

This is a retrospective study of 60 paediatric optic pathway glioma (OPG) patients (NF1 or sporadic) presenting to Great Ormond Street between 2003-2017. Median follow-up was 82 months. Analysis was divided into best and worst eye vision representing level quality...

Stereotactic radiotherapy for polypoidal choroidal vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...

Orbital Schwannomas

This is a large case series of orbital Schwannomas managed at a single centre over a 26-year period. Twenty Schwannomas are reported, all but one of which was managed surgically. The tumours were all benign, had an insidious onset and...

An anterior segment lump: a diagnostic and treatment challenge

Case presentation A 50-year-old female presented to eye casualty with a lump on the left medial lower eyelid with associated redness and occasional bleeding. The lump was present for a few months with recent enlargement (Figure 1). Her past medical...

Atopic keratoconjunctivitis (AKC) and ocular surface squamous neoplasia (OSSN)

The authors present two cases of invasive OSSN in patients with severe AKC. Case 1 was a 73-year-old male with severe AKC and atopic eczema who developed a suspicious papillary-like limbal lesion in the left eye. He had an excisional...

Leadership skills training through the COECSA-RCOphth LINK

The Lead Forward project was an initiative of the VISION 2020 LINKS Programme, funded by the Department for International Development (DFID) via the Tropical Health Education Trust (THET). It aimed to improve the quality of medical leadership within VISION 2020...

Second primary tumours after sebaceous carcinoma

This is a study investigating the risk of developing a second primary malignancy in patients previously diagnosed with eyelid sebaceous cell carcinoma. The records of 559 patients who were diagnosed with sebaceous cell carcinoma between 2000 and 2016 were reviewed,...

Therapeutic options for advanced cutaneous basal (BCC) and squamous cell carcinomas (SCC)

This article discusses the use of topical and systemic therapy in the management of advanced periocular tumours. It focuses on those that have gained United States Food and Drug Administration approval; namely imiquimod, vismodegib, sonidegib, pembrolizumab and cemiplimab. Imiquimod is...

Ophthalmic presentations and outcomes in Erdheim-Chester disease

This is a comprehensive article describing clinical manifestations and pathogenesis of Erdheim-Chester disease (ECD) followed by a literature review of the available treatments. The authors look to compare historical treatment (HT) with vemurafenib, a BRAF inhibitor. ECD is a non-Langerhans...

Visual outcomes, visual fields and optical coherence tomography in paediatric craniopharyngioma

This study reviews the visual outcomes of ten patients under the age of 18 years with craniopharyngioma. The paper also reviews the correlation between visual field (VF) testing and optical coherence tomography (OCT) examination and evaluates the role of OCT...

Germline mutation risk in solitary unilateral retinoblastoma

This study aimed to determine the true risk for germline mutation in a child presenting with solitary unilateral RB and whether this risk differs by age at presentation. This was a retrospective review of 482 cases from 1972-2020. Age groups...